Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.

Murase, Katsuyuki; Lee, Lucy; Ma, Jiyuan; Barrett, Rosemary; Thoolen, Martin

Murase, Katsuyuki; Lee, Lucy; Ma, Jiyuan; Barrett, Rosemary; Thoolen, Martin.

Afiliación

Murase K; PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, 07080, USA.
Lee L; PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, 07080, USA.
Ma J; PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, 07080, USA.
Barrett R; PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, 07080, USA.
Thoolen M; PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ, 07080, USA. mthoolen@ptcbio.com.

Eur J Clin Pharmacol ; 78(11): 1823-1831, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36166059

Asunto(s)

Omeprazol; Tolbutamida; Área Bajo la Curva; Citocromo P-450 CYP2C19/metabolismo; Citocromo P-450 CYP2C9/metabolismo; Sistema Enzimático del Citocromo P-450/metabolismo; Interacciones Farmacológicas; Voluntarios Sanos; Humanos; Omeprazol/farmacología; Tolbutamida/farmacocinética

Palabras clave

CYP inhibition; Drug-drug interactions; Healthy volunteers; Pharmacokinetics; Vatiquinone

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tolbutamida / Omeprazol Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google